{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:48:25Z","timestamp":1777369705956,"version":"3.51.4"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1097\/jcp.0b013e318222b5dd","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T06:49:40Z","timestamp":1308638980000},"page":"463-469","source":"Crossref","is-referenced-by-count":69,"title":["CYP2B6 Polymorphisms Influence the Plasma Concentration and Clearance of the Methadone S-Enantiomer"],"prefix":"10.1097","volume":"31","author":[{"given":"Sheng-Chang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ing-Kang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiao-Hui","family":"Tsou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Ni","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Fu","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Happy Kuy-Lok","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Shin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lien-Wen","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh-Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Lun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keh-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu Chih","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiao-Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiu-Wen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Hsien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Sheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-10-20210128","doi-asserted-by":"crossref","first-page":"L45","DOI":"10.1016\/0024-3205(94)00937-6","article-title":"The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine.","volume":"56","author":"Kristensen","year":"1995","journal-title":"Life Sci"},{"key":"R3-10-20210128","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0b013e318192eb00","article-title":"Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients.","volume":"29","author":"Elkader","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"R4-10-20210128","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","article-title":"Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers.","volume":"81","author":"Eap","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R5-10-20210128","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/chir.10303","article-title":"Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.","volume":"16","author":"Gerber","year":"2004","journal-title":"Chirality"},{"key":"R6-10-20210128","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1124\/dmd.31.6.742","article-title":"Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.","volume":"31","author":"Wang","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R7-10-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","article-title":"Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.","volume":"78","author":"Crettol","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R8-10-20210128","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/138920008785821710","article-title":"CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.","volume":"9","author":"Wang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"R9-10-20210128","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0090-9556(24)15302-0","article-title":"Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.","volume":"27","author":"Roy","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"R10-10-20210128","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.","volume":"306","author":"Ward","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R11-10-20210128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","article-title":"Role of CYP2B6 in stereoselective human methadone metabolism.","volume":"108","author":"Totah","year":"2008","journal-title":"Anesthesiology"},{"key":"R12-10-20210128","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":"Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.","volume":"116","author":"Ingelman-Sundberg","year":"2007","journal-title":"Pharmacol Ther"},{"key":"R13-10-20210128","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2217\/14622416.8.7.743","article-title":"Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.","volume":"8","author":"Zanger","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R14-10-20210128","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","article-title":"Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation.","volume":"392","author":"Zanger","year":"2008","journal-title":"Anal Bioanal Chem"},{"key":"R15-10-20210128","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/bmc.1363","article-title":"Development of a method to measure methadone enantiomers and its metabolites without enantiomer standard compounds for the plasma of methadone maintenance patients.","volume":"24","author":"Wang","year":"2010","journal-title":"Biomed Chromatogr"},{"key":"R16-10-20210128","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1111\/j.1360-0443.2008.02284.x","article-title":"Development of the treatment outcomes profile.","volume":"103","author":"Marsden","year":"2008","journal-title":"Addiction"},{"key":"R18-10-20210128","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/bmc.1363","article-title":"Development of a method to measure methadone enantiomers and its metabolites without enantiomer standard compounds for the plasma of methadone maintenance patients.","volume":"24","author":"Wang","year":"2010","journal-title":"Biomed Chromatogr"},{"key":"R19-10-20210128","doi-asserted-by":"crossref","first-page":"W635","DOI":"10.1093\/nar\/gkl236","article-title":"FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization.","volume":"34","author":"Yuan","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"R21-10-20210128","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clinbiochem.2004.12.005","article-title":"Genotyping single nucleotide polymorphisms by MALDI mass spectrometry in clinical applications.","volume":"38","author":"Tost","year":"2005","journal-title":"Clin Biochem"},{"key":"R22-10-20210128","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","article-title":"Haploview: analysis and visualization of LD and haplotype maps.","volume":"21","author":"Barrett","year":"2005","journal-title":"Bioinformatics"},{"key":"R23-10-20210128","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1086\/379378","article-title":"A comparison of bayesian methods for haplotype reconstruction from population genotype data.","volume":"73","author":"Stephens","year":"2003","journal-title":"Am J Hum Genet"},{"key":"R26-10-20210128","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","article-title":"Haploview: analysis and visualization of LD and haplotype maps.","volume":"21","author":"Barrett","year":"2005","journal-title":"Bioinformatics"},{"key":"R27-10-20210128","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1128\/AAC.48.11.4148-4153.2004","article-title":"Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients.","volume":"48","author":"Stocker","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-10-20210128","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-9556(24)15284-1","article-title":"Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450.","volume":"27","author":"Busby","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"R29-10-20210128","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0028-3908(03)00136-9","article-title":"Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain.","volume":"45","author":"Miksys","year":"2003","journal-title":"Neuropharmacology"},{"key":"R30-10-20210128","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2125.1999.00921.x","article-title":"Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4.","volume":"47","author":"Foster","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R31-10-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0376-8716(02)00320-4","article-title":"Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses.","volume":"69","author":"Shinderman","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"R32-10-20210128","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/ALN.0b013e3181986a9a","article-title":"Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir\/indinavir.","volume":"110","author":"Kharasch","year":"2009","journal-title":"Anesthesiology"},{"key":"R33-10-20210128","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2174\/187231208786734067","article-title":"Increase of R-\/S-methadone enantiomer concentration ratio in serum of patients treated with either nevirapine or efavirenz.","volume":"2","author":"Esteban","year":"2008","journal-title":"Drug Metab Lett"},{"key":"R34-10-20210128","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1592\/phco.28.7.863","article-title":"Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.","volume":"28","author":"Cao","year":"2008","journal-title":"Pharmacotherapy"},{"key":"R35-10-20210128","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1530-0277.1985.tb05558.x","article-title":"Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients.","volume":"9","author":"Novick","year":"1985","journal-title":"Alcohol Clin Exp Res"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-201108000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T12:29:30Z","timestamp":1741264170000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201108000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318222b5dd","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}